|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1998-9-1
|
|
pubmed:abstractText |
5-Fluorouracil (5-FU), as a single agent, produces a 15% response rate in advanced squamous cell carcinoma of the head and neck (SCCHN). N-phosphonacetyl-L-aspartate (PALA) inhibits pyrimidine biosynthesis and increases incorporation of 5-FU metabolites into ribonucleic acid (RNA). Recombinant alpha interferon-2b (rIFN-alpha-2b) may inhibit 5-FU clearance and blunt reflex rise in thymidylate synthetase, therefore enhancing inhibition of the target enzyme of 5-FU.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1043-3074
|
|
pubmed:author |
pubmed-author:AliTT,
pubmed-author:ClarkJJ,
pubmed-author:DeMariaDD,
pubmed-author:JohnsonCC,
pubmed-author:LangerC JCJ,
pubmed-author:LeightonJJ,
pubmed-author:LitwinSS,
pubmed-author:ReillyD MDM,
pubmed-author:RidgeJ AJA,
pubmed-author:SauterEE,
pubmed-author:SchaeblerDD
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
385-91
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:9663665-Adult,
pubmed-meshheading:9663665-Aged,
pubmed-meshheading:9663665-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9663665-Aspartic Acid,
pubmed-meshheading:9663665-Carcinoma, Squamous Cell,
pubmed-meshheading:9663665-Drug Administration Schedule,
pubmed-meshheading:9663665-Female,
pubmed-meshheading:9663665-Fluorouracil,
pubmed-meshheading:9663665-Genes, p53,
pubmed-meshheading:9663665-Head and Neck Neoplasms,
pubmed-meshheading:9663665-Humans,
pubmed-meshheading:9663665-Interferon-alpha,
pubmed-meshheading:9663665-Male,
pubmed-meshheading:9663665-Middle Aged,
pubmed-meshheading:9663665-Mutation,
pubmed-meshheading:9663665-Neoplasm Recurrence, Local,
pubmed-meshheading:9663665-Phosphonoacetic Acid,
pubmed-meshheading:9663665-Survival Analysis,
pubmed-meshheading:9663665-Treatment Failure
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Phase II study of N-phosphonacetyl-L-aspartate, recombinant interferon-alpha, and fluorouracil infusion in advanced squamous cell carcinoma of the head and neck.
|
|
pubmed:affiliation |
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
